EGFR and breast carcinoma: Sano et al. [30] described using the NIR-labeled human anti-epidermal growth factor receptor (EGFR) (panitumumab) and indocyanine green (ICG) conjugated with human anti-epidermal growth factor receptor type 2 (HER2) (trastuzumab) to obtain a multi-color target-specific fluorescence breast cancer imaging in an in vivo mouse model.